Therapeutics for 'Silent' Cancers
The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a compound annual growth rate (CAGR) of 8.5% from 2014 to 2019.
- An overview of the global markets and technologies for the therapeutics for "silent" cancers.
- Analyses of global market trends, with data from 2013, 2014, and projections of CAGRs through 2019.
- Descriptions of cancers, with incidence and prevalence data for all major national markets.
- Assessments of currently available therapies.
- Evaluation of new agents now in clinical development, with likely launch timetables and estimates of potential clinical value.
- Profiles of major players in the "silent" cancer therapeutics industry.
SCOPE OF REPORT
The report discusses eight cancers described as “silent and deadly” because they are often undiagnosed until the diseases is advanced and difficult to treat. These cancers are brain, cervix, esophagus, mouth and larynx, ovary, pancreas, kidney, and lastly, liver. For each cancer, the cause, clinical course, diagnosis and treatment are described. Current drug therapy is outlined and new research activities are listed. The market is summarized and quantified for each cancer, with estimates of recent (2013) and current (2014) values for each cancer, and five-year projection to 2019. Geographically, the global market is given, with country analyses for the U.S., Japan, and five major Western European markets: Germany, France, Italy, Spain and the United Kingdom.
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the cancer marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.